Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 14.79% is 16% above its 5-year average of 12.80%, around the middle of its 5-year range (7.31%–20.16%).
0.15% below its 12-month average of 14.81%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 14.07%.
GROSS MARGIN
14.79%
GROSS MARGIN AVG TTM
14.81%
GROSS MARGIN AVG 3Y
13.30%
GROSS MARGIN AVG 5Y
12.80%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.15%
CURRENT VS 3Y AVG
+11.18%
CURRENT VS 5Y AVG
+15.52%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-64.26%
vs the sector median at left
The Pennant Group, Inc.
Market Cap
$1.39B
Gross Margin
14.79%
TTM Avg
14.81%
3Y Avg
13.30%
5Y Avg
12.80%
Market Cap
$1.40B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.40B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
75.15%
5Y Avg
50.10%
Market Cap
$1.37B
Gross Margin
-91.00%
TTM Avg
-566.75%
3Y Avg
-1506.60%
5Y Avg
-994.02%
Market Cap
$1.42B
Gross Margin
98.97%
TTM Avg
9.74%
3Y Avg
-353.69%
5Y Avg
-246.22%
Market Cap
$1.42B
Gross Margin
83.12%
TTM Avg
85.05%
3Y Avg
87.98%
5Y Avg
90.85%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| The Pennant Group, Inc. (PNTG) | $1.39B | 14.79% | 14.81% | 13.30% | 12.80% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.40B | 0.00% | 0.00% | 0.00% | 0.00% |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | 100.00% | 100.00% | 75.15% | 50.10% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | -91.00% | -566.75% | -1506.60% | -994.02% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 98.97% | 9.74% | -353.69% | -246.22% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | 83.12% | 85.05% | 87.98% | 90.85% |
| Omeros Corporation (OMER)vs › | $1.34B | 0.00% | 0.00% | 0.00% | 0.00% |
| Certara, Inc. (CERT)vs › | $1.44B | 58.33% | 60.70% | 60.53% | 60.29% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 17.33% | 13.16% | 12.65% | 13.31% |
Gross Margin
14.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 14.07% |
| 2026-03-31 | 13.10% |
| 2025-12-31 | 12.93% |
| 2025-09-30 | 20.16% |
| 2025-06-30 | 13.80% |
| 2025-03-31 | 14.00% |
| 2024-12-31 | 13.24% |
| 2024-09-30 | 14.01% |
| 2024-06-30 | 13.58% |
| 2024-03-31 | 13.09% |
| 2023-12-31 | 12.81% |
| 2023-09-30 | 12.70% |
| 2023-06-30 | 12.30% |
| 2023-03-31 | 11.28% |
| 2022-12-31 | 12.98% |
| 2022-09-30 | 12.07% |
| 2022-06-30 | 12.48% |
| 2022-03-31 | 11.86% |
| 2021-12-31 | 7.31% |
| 2021-09-30 | 10.69% |
| 2021-06-30 | 12.25% |
| 2021-03-31 | 11.43% |
| 2020-12-31 | 13.83% |
| 2020-09-30 | 13.40% |
| 2020-06-30 | 15.97% |
| 2020-03-31 | 13.01% |
| 2019-12-31 | 12.29% |
| 2019-09-30 | 13.09% |
| 2019-06-30 | 13.49% |
| 2019-03-31 | 13.97% |
| 2018-12-31 | 14.46% |
| 2018-09-30 | 15.09% |
| 2018-06-30 | 25.69% |
| 2018-03-31 | 26.33% |
